HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Aleix Prat, Tomás Pascual et al.|npj Breast Cancer|2025Cited by 6
13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratificationRodrigo Sánchez-Bayona, Eva Ciruelos, O. Martínez-Sáez et al.|ESMO Open|2024Cited by 1
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Fara Brasó-Maristany, Sandra Cobo et al.|npj Breast Cancer|2026Cited by 0
Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THPMarcin Kubeczko, F. Braso-Maritany, Sandra Cobo et al.|Clinical Cancer Research|2026Cited by 0